reason report
teplizumab path confirm remain cours file
bottom line prvb share feedback receiv fda
summar outcom novemb type meet
manag made number import updat fda requir
follow-up trial fda request histor data impact teplizumab
c-peptid manufactur remain track bottleneck file
complet roll basi detail follow-up
convers manag continu view teplizumab
paradigm shift approach type diabet treatment
specif potenti autoimmun broadli
manag emphas highli collabor encourag
tone fda got everyth ask type
meet focus clinic data prvb requir file
establish expect chemistri manufactur control
valid file bla file specif focu
gain approv patient at-risk develop manag
vehement new onset indic prior protect readout
pictur didnt ask fda request teplizumab
bla file roll submiss basi manag punt
whether would equival roll review allow
compani receiv feedback fda submit modul
critiqu address subsequ modul submiss may
add addit time review complet modul
fda may formal review modul submit point
specul whether happen
fda look efficaci safeti data date includ
c-peptid although at-risk trial evalu clinic relev
endpoint time diagnosi fda request review
efficaci data date includ c-peptid measur prior trial
new onset patient c-peptid consid surrog beta cell
mass pancrea preserv consid big plu
treatment monitor type patient fda request
quit consist histor request data file allow
understand patient treatment behav instanc
see request addit data determin binari
outcom risk trial add bodi evid
support teplizumab efficaci preserv -cell function measur
c-peptid stabil word expect request
anoth risk trial pend evalu c-peptid result older
studi patient dose date fda consid
safeti data on-hand suffici file
readthrough protect c-peptid review
ask expect get new onset label current
file despit review c-peptid data wont contribut
acceler label new onset patient given fact approv
sotp analysi discount
rate termin growth rate
year price history/av daili volume mil prvb
compani inform svb leerink llc research
revenu quarterli ep may sum annual total due chang share outstand
pleas refer page import disclosur price chart analyst certif
new onset requir addit data clinic endpoint includ
differ insulin use time hypoglycemia
forese approv new onset patient prior complet
protect trial manag provid guidanc protect
track fulli enrol
manufactur final pin stand track prvb
contract manufactur organ agc biolog expect produc
engin batch end year follow three
process perform batch must produc sequenti
expect complet cross batch comparison comparison
drug use clinic trial perform submit part
compar packag fda evalu valid
compar test requir prvb guid file
modul bla earli
teplizumab valu evolv time project initi
peak sale teplizumab vs base sole
approv at-risk patient singl cours price
peak sale project expand teplizumab gain label
expans new onset patient earli screen program
becom establish identifi risk patient rel
patient valu realiz teplizumab gain approv
ex-u market estim approv would roughli
doubl number elig patient prvb alreadi receiv prime
design ema guid regulatori process trail
 timelin year
risk valuat stock increas price target
per share base updat provid prvb
expect commerci launch teplizumab at-risk patient
within sum part valuat at-risk indic
probabl technic regulatori success ptr add per
share overal valuat new onset indic teplizumab
oper expens per share reconcil current pt
sensit analysi indic per share chang price target
everi quarter differ commerci launch teplizumab at-risk
take whirlwind journey prvb long
one teplizumab near finish line least help
patient risk reiter drug first
new wave drug see next year begin
reprogram immun system reduc impact intoler
clone enabl opportun re-establish toler holi
grail immunolog one step closer realiti hail mari
approach trialnet jdrf took watch close prvb safekeep
asset rest commun finish line
continu insid discuss commerci opportun find
patient teplizumab futur
assign provent share outperform rate price target prvb
maxim valu re-engag develop drug sidelin due
clinic failur caus poor trial design
target wrong diseas
sinc announc posit result teplizumab american diabet
associ ada confer june prvb focus guid treatment
regulatori process seek approv use patient risk develop type
prvb leverag partnership build ambiti portfolio focus prevent
delay autoimmun inflammatori diseas onset
experienc leadership team direct prior experi sever asset includ
commerci opportun at-risk initi limit manag estim patient
least autoantibodi aab dysglycemia at-risk group base
diagnos annual probabl diseas at-risk patient
estim patient age highli access due
famili relat patient repres total address market howev
find patient requir extens screen program use current avail
screen methodolog possibl scenario near term highli improb
view estim autoimmun patient younger diagnos annual
patient degre rel patient repres
easili identifi patient repres first year post launch
patient find drug way around discuss medacorp kol
suggest wareh patient find addit patient requir
extens screen program current sit infanc pilot program current
oper select citi nation outsid pilot program major earli
patient like found concert effort patient get
screen auto-ab dynam shift screen program evolv expand
time howev drive effort requir hands-on-deck approach highli invest
parti juvenil diabet research foundat jdrf helmsley foundat
teplizumab futur manag reiter interest look re-dos combin
strategi teplizumab spoke multipl medacorp kol indic teplizumab could
becom backbon combin idea suppress wayward cell follow
induc regulatori control dream across inflamm immunolog mani
kol spoken suggest follow sequenc teplizumab follow mutein
teplizumab follow adalimumab agent ask anti-tnf
mainten dose approach note golimumab trial conduct janssen op
readout expect kol balk idea indefinit treat patient
ani-tnf agent teplizumab approv would expect combin trial
get start manag state intent develop subq formul suggest
would open door tri teplizumab indic autoimmun hepat crohn
diseas celiac diseas rheumatoid arthriti
revenu project
sum-of-the-part analysi wacc-calcul discount rate
termin growth rate appli
sum-of-the-part analysi arriv price target per share
 cost consid part oper
asset valuat adjust probabl receiv regulatori approv base
histor fda approv rate
strateg risk prvb greatest risk lie compani size rel portfolio size
decis maintain streamlin oper strategi help extend cash
runway also make execut clinic trial difficult may result
failur achiev target mileston timelin
financ risk abil rais addit fund crucial continu
development cours across compani pipelin inabl rais suffici fund
need may result program triag offload asset abil rais suffici
capit may difficult due higher need fund pipelin prvb
size stage develop typic requir
licens risk call back provis relat prvb
licens agreement janssen respect factor
impact activ call back provis would valuat
prvb full impact truli account within valuat methodolog
without project potenti date and/or probabl provis activ
regulatori risk teplizumab prvb engag fda seek
expedit approv teplizumab patient risk type diabet outcom
time fda decis impact precis launch valuat teplizumab
brand
type event
event trial detail
date known
up/down
expect
annouc
phase data phase prevail trial
janssen decid whether recal prv-
initi phase portion phase prevail
svb leerink llc equiti research compani file
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
growth profit ratio
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce underwrittend public offer net
proce privat placement amgen
proce issuanc seri convert redeem prefer
proce exercis warrant stock option
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce underwrittend public offer net
proce privat placement amgen
proce issuanc seri convert redeem prefer
proce exercis warrant stock option
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
